Overview

Study of Bexxar Combined With External Beam Radiation Therapy

Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the response rate of patients with relapsed or refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma to Iodine-131 (I-131) tositumomab (Bexxar) therapy plus local palliative radiation therapy (XRT).
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal
Iodine
Iodine-131 anti-B1 antibody
Lugol's solution
Pharmaceutical Solutions